Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 71.0%

Neg 0% Neu 71% Pos 0%

Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and announces $5 price target.